NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
Clinical Trials
4 trialsNCT02573220 2016-12-09
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
University of Chicago
Phase 1 Withdrawn
NCT02055196 2014-06-02
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT01605344 2014-02-27
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
UNC Lineberger Comprehensive Cancer Center
Phase 1 Withdrawn